Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)

0.0475
-0.0365-43.45%
Volume:69.16K
Turnover:4.29K
Market Cap:- -
PE:-0.01
High:0.0700
Open:0.0700
Low:0.0450
Close:0.0840
52wk High:0.1750
52wk Low:0.0202
Shares:- -
Float Shares:- -
Volume Ratio:3.02
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3487
ROE:-274.77%
ROA:-145.01%
PB:0.00
PE(LYR):- -

Loading ...

Company Profile

Company Name:
CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Website:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.